Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX) in a research report report published on Monday morning,Benzinga reports. Chardan Capital currently has a $6.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Unity Biotechnology in a research note on Monday.

Unity Biotechnology Stock Down 4.8 %

Shares of UBX stock opened at $1.60 on Monday. The company has a 50 day moving average of $1.84 and a 200-day moving average of $1.51. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10. The firm has a market cap of $26.96 million, a P/E ratio of -1.22 and a beta of 1.02.

Institutional Investors Weigh In On Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC boosted its holdings in Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,242 shares of the company’s stock after buying an additional 14,199 shares during the period. Geode Capital Management LLC owned approximately 0.97% of Unity Biotechnology worth $240,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.